Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2010

01-12-2010 | Brief Report

Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer

Authors: Yonglan Zheng, Jing Zhang, Kisha Hope, Qun Niu, Dezheng Huo, Olufunmilayo I. Olopade

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Login to get access

Abstract

It has been reported that one biallelic missense mutation in the RAD51C gene was found in a Fanconi anemia-like disorder and six monoallelic pathogenic mutations were identified in 480 BRCA1/2 negative breast and ovarian cancer pedigrees but not in 620 pedigrees with breast cancer only. Additionally, the RAD51C gene was reported to be involved in gene fusion events in the MCF-7 breast cancer cell line. We performed complete sequencing and fusion gene breakpoint screening to detect deleterious mutations and chromosomal structure change in the RAD51C gene. Ninety-two hereditary gynecological cancer patients with a family history of breast and ovarian cancer but not carrying BRCA1/2 mutations were studied. In addition, 46 breast cancer cell lines were screened for the gene fusion events. Ten DNA sequence variants but no deleterious mutations were identified. We did not observe the occurrence of the known gene fusion either. We were unable to confirm the contribution of the RAD51C gene to hereditary breast and ovarian cancer (HBOC) in this relatively small cohort. Nonetheless, larger studies in diverse populations to fully investigate the mutation spectrum of the RAD51C gene are needed.
Literature
3.
go back to reference Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, Wurm M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, Tischkowitz M, Mathew CG, Auerbach AD, Rahman N (2007) Biallelic mutations in palb2 cause Fanconi anemia subtype fa-n and predispose to childhood cancer. Nat Genet 39(2):162–164. doi:10.1038/ng1947 CrossRefPubMed Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, Wurm M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, Tischkowitz M, Mathew CG, Auerbach AD, Rahman N (2007) Biallelic mutations in palb2 cause Fanconi anemia subtype fa-n and predispose to childhood cancer. Nat Genet 39(2):162–164. doi:10.​1038/​ng1947 CrossRefPubMed
4.
go back to reference Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J, Wang W, Livingston DM, Joenje H, de Winter JP (2007) Fanconi anemia is associated with a defect in the brca2 partner palb2. Nat Genet 39(2):159–161. doi:10.1038/ng1942 CrossRefPubMed Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J, Wang W, Livingston DM, Joenje H, de Winter JP (2007) Fanconi anemia is associated with a defect in the brca2 partner palb2. Nat Genet 39(2):159–161. doi:10.​1038/​ng1942 CrossRefPubMed
5.
go back to reference Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, Fraternali F, Freund M, Hartmann L, Grimwade D, Roberts RG, Schaal H, Mohammed S, Rahman N, Schindler D, Mathew CG (2010) Mutation of the rad51c gene in a Fanconi anemia-like disorder. Nat Genet 42(5):406–409. doi:10.1038/ng.570 CrossRefPubMed Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, Fraternali F, Freund M, Hartmann L, Grimwade D, Roberts RG, Schaal H, Mohammed S, Rahman N, Schindler D, Mathew CG (2010) Mutation of the rad51c gene in a Fanconi anemia-like disorder. Nat Genet 42(5):406–409. doi:10.​1038/​ng.​570 CrossRefPubMed
6.
go back to reference Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K, Deissler H, Engel C, Muller-Myhsok B, Neveling K, Kiechle M, Mathew CG, Schindler D, Schmutzler RK, Hanenberg H (2010) Germline mutations in breast and ovarian cancer pedigrees establish rad51c as a human cancer susceptibility gene. Nat Genet 42(5):410–414. doi:10.1038/ng.569 CrossRefPubMed Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K, Deissler H, Engel C, Muller-Myhsok B, Neveling K, Kiechle M, Mathew CG, Schindler D, Schmutzler RK, Hanenberg H (2010) Germline mutations in breast and ovarian cancer pedigrees establish rad51c as a human cancer susceptibility gene. Nat Genet 42(5):410–414. doi:10.​1038/​ng.​569 CrossRefPubMed
7.
go back to reference Hampton OA, Den Hollander P, Miller CA, Delgado DA, Li J, Coarfa C, Harris RA, Richards S, Scherer SE, Muzny DM, Gibbs RA, Lee AV, Milosavljevic A (2009) A sequence-level map of chromosomal breakpoints in the mcf-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res 19(2):167–177. doi:10.1101/gr.080259.108 CrossRefPubMed Hampton OA, Den Hollander P, Miller CA, Delgado DA, Li J, Coarfa C, Harris RA, Richards S, Scherer SE, Muzny DM, Gibbs RA, Lee AV, Milosavljevic A (2009) A sequence-level map of chromosomal breakpoints in the mcf-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res 19(2):167–177. doi:10.​1101/​gr.​080259.​108 CrossRefPubMed
12.
go back to reference Berwick M, Satagopan JM, Ben-Porat L, Carlson A, Mah K, Henry R, Diotti R, Milton K, Pujara K, Landers T, Dev Batish S, Morales J, Schindler D, Hanenberg H, Hromas R, Levran O, Auerbach AD (2007) Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res 67(19):9591–9596. doi:10.1158/0008-5472.CAN-07-1501 CrossRefPubMed Berwick M, Satagopan JM, Ben-Porat L, Carlson A, Mah K, Henry R, Diotti R, Milton K, Pujara K, Landers T, Dev Batish S, Morales J, Schindler D, Hanenberg H, Hromas R, Levran O, Auerbach AD (2007) Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res 67(19):9591–9596. doi:10.​1158/​0008-5472.​CAN-07-1501 CrossRefPubMed
13.
go back to reference Barlund M, Monni O, Kononen J, Cornelison R, Torhorst J, Sauter G, Kallioniemi O-P, Kallioniemi A (2000) Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res 60(19):5340–5344PubMed Barlund M, Monni O, Kononen J, Cornelison R, Torhorst J, Sauter G, Kallioniemi O-P, Kallioniemi A (2000) Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res 60(19):5340–5344PubMed
14.
go back to reference Wu GJ, Sinclair CS, Paape J, Ingle JN, Roche PC, James CD, Couch FJ (2000) 17q23 amplifications in breast cancer involve the pat1, rad51c, ps6k, and sigma1b genes. Cancer Res 60(19):5371–5375PubMed Wu GJ, Sinclair CS, Paape J, Ingle JN, Roche PC, James CD, Couch FJ (2000) 17q23 amplifications in breast cancer involve the pat1, rad51c, ps6k, and sigma1b genes. Cancer Res 60(19):5371–5375PubMed
19.
go back to reference Smeenk G, de Groot AJ, Romeijn RJ, van Buul PP, Zdzienicka MZ, Mullenders LH, Pastink A, Godthelp BC (2010) Rad51c is essential for embryonic development and haploinsufficiency causes increased DNA damage sensitivity and genomic instability. Mutat Res 689(1–2):50–58. doi:10.1016/j.mrfmmm.2010.05.001 PubMed Smeenk G, de Groot AJ, Romeijn RJ, van Buul PP, Zdzienicka MZ, Mullenders LH, Pastink A, Godthelp BC (2010) Rad51c is essential for embryonic development and haploinsufficiency causes increased DNA damage sensitivity and genomic instability. Mutat Res 689(1–2):50–58. doi:10.​1016/​j.​mrfmmm.​2010.​05.​001 PubMed
Metadata
Title
Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer
Authors
Yonglan Zheng
Jing Zhang
Kisha Hope
Qun Niu
Dezheng Huo
Olufunmilayo I. Olopade
Publication date
01-12-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1095-5

Other articles of this Issue 3/2010

Breast Cancer Research and Treatment 3/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine